Search research articles
Contact Us
Filters
Showing results (1-10 of 88) with videos related to
Page
of 9
Sort By:
JAMA Neurology
|
December 29, 2025
Beyond the Single-Disease Paradigm-Why Distinctions in Multiple Sclerosis Still Matter
Afsaneh Shirani, Olaf Stuve
Therapeutic Advances in Neurological Disorders
|
February 23, 2026
Vedolizumab and the gut-CNS axis in multiple sclerosis: considering T cell licensing pathways
Afsaneh Shirani, Olaf Stuve
The Lancet. Neurology
|
July 23, 2013
Progressive multiple sclerosis: desperately seeking remedy
Olaf Stuve, Friedemann Paul
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 5, 2025
Remyelination therapies are achievable in clinical practice-No
Afsaneh Shirani, Olaf Stuve
Expert Opinion on Investigational Drugs
|
November 6, 2025
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions
Afsaneh Shirani, Olaf Stuve
Frontiers in Molecular Neuroscience
|
June 30, 2023
Editorial: Animal models of multiple sclerosis: can they advance future therapies?
Tara Maria DeSilva, Olaf Stuve
Neurology(R) Neuroimmunology & Neuroinflammation
|
March 12, 2020
Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
John F Foley, Olaf Stuve
Frontiers in Immunology
|
August 29, 2022
The role of the complement system in Multiple Sclerosis: A review
Nil Saez-Calveras, Olaf Stuve
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 6, 2016
Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
Thomas G Forsthuber, Olaf Stuve
Neurology(R) Neuroimmunology & Neuroinflammation
|
December 28, 2020
Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy
Navid Manouchehri, Lawrence Steinman, Olaf Stuve
Page
of 9
Search research articles
Search
Showing results (1-10 of 88) with videos related to
Sort By:
Page
of 9
JAMA Neurology
|
December 29, 2025
Beyond the Single-Disease Paradigm-Why Distinctions in Multiple Sclerosis Still Matter
Afsaneh Shirani, Olaf Stuve
Therapeutic Advances in Neurological Disorders
|
February 23, 2026
Vedolizumab and the gut-CNS axis in multiple sclerosis: considering T cell licensing pathways
Afsaneh Shirani, Olaf Stuve
The Lancet. Neurology
|
July 23, 2013
Progressive multiple sclerosis: desperately seeking remedy
Olaf Stuve, Friedemann Paul
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 5, 2025
Remyelination therapies are achievable in clinical practice-No
Afsaneh Shirani, Olaf Stuve
Expert Opinion on Investigational Drugs
|
November 6, 2025
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions
Afsaneh Shirani, Olaf Stuve
Frontiers in Molecular Neuroscience
|
June 30, 2023
Editorial: Animal models of multiple sclerosis: can they advance future therapies?
Tara Maria DeSilva, Olaf Stuve
Neurology(R) Neuroimmunology & Neuroinflammation
|
March 12, 2020
Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
John F Foley, Olaf Stuve
Frontiers in Immunology
|
August 29, 2022
The role of the complement system in Multiple Sclerosis: A review
Nil Saez-Calveras, Olaf Stuve
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 6, 2016
Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
Thomas G Forsthuber, Olaf Stuve
Neurology(R) Neuroimmunology & Neuroinflammation
|
December 28, 2020
Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy
Navid Manouchehri, Lawrence Steinman, Olaf Stuve
Page
of 9